707 Cayman Holdings Ltd (JEM) Stock Analysis
Verdict: AVOID
Pivot to pharma via $10.25M term sheet triggers a rally, but FY25 operating losses (-40.1M HKD) and dilution threaten sustainability.
Investment score: 25/100
Analysis as of
Is 707 Cayman Holdings Ltd stock worth reviewing? AI model thesis
The AI model evaluates 707 Cayman Holdings (JEM) as an AVOID. Despite a single-session pop of 77.88% to $6.80 following an acquisition term sheet with $10.25M in committed financing, the company's severe FY2025 operational loss (-40.1M HKD) and massive historical price erosion make capital risk unacceptably high.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
707 Cayman Holdings Ltd opportunities and risks
What speaks for JEM
- Announced term sheet for Crucial Innovation with $10.25M committed financing
What speaks against JEM
- Operational performance collapsed into a -40.06M HKD operating loss in FY2025
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| JEM | 156.7x | 0.1x | n/a | 29.1% | 8.5% | 59.0% |
| SORA | 32.5x | 37.4x | n/a | 2.6% | 111.9% | -1.1% |
| RAY | 3.6x | 0.4x | n/a | 27.6% | 11.7% | -28.7% |
| JL | 51.9x | 3.4x | 36.2x | 34.0% | 6.5% | 0.0% |
| Peer median | 32.5x | 3.4x | n/a | 27.6% | 11.7% | -1.1% |
Frequently asked questions about 707 Cayman Holdings Ltd (JEM)
Is JEM stock a good investment?
The cached TradeMates AI model rates 707 Cayman Holdings Ltd as AVOID with an investment score of 25/100. The AI model evaluates 707 Cayman Holdings (JEM) as an AVOID. Despite a single-session pop of 77.88% to $6.80 following an acquisition term sheet with $10.25M in committed financing, the company's severe FY2025 operational loss (-40.1M HKD) and massive historical price erosion make capital risk unacceptably high. This is algorithmic model output, not personal investment advice.
Is JEM stock a buy?
The TradeMates model verdict for JEM is AVOID with an investment score of 25/100. Treat this as a model signal to review, not a personal buy recommendation.